Companies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Moonlake Aims To Defy The Single-Product Risk
The group is pushing sonelokimab into pivotal trials in two indications and starting from scratch in three more. What comes after that?
Moeller Looks To Prove BenevolentAI’s Doubters Wrong
The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
Mission Therapeutics Raises Funds For Parkinson’s Disease Protein Modulator
New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.
BeiGene’s Oncology Market 'Disruption' Gains Pace Despite Tevimbra Travails
The Sino-American company believes faster, lower-cost R&D and competitive pricing and access will give it an edge in oncology. Its chief commercial officer for North America and Europe told Scrip how it is now looking to repeat the success of Brukinsa and finally launch its much-delayed PD-1 inhibitor Tevimbra.
Roche Looks To Defy The Odds In Parkinson’s Study
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.
Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent
Galderma presented long-term extension data from its Phase III trials in atopic dermatitis and prurigo nodularis at AAD for its first-ever therapeutic biologic, taking on a formidable competitor.
Incyte Aims At Mild Hidradenitis Suppurativa
A Phase II hit with a topical product could enable a move into an untreated form of the condition.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.
Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again
The US FDA wants to hold an advisory committee meeting for Lilly’s donanemab in early Alzheimer’s disease, which means approval will now occur after the expected Q1 decision date.
Ultimovacs Suffers From Melanoma Failure
Its cancer vaccine UV1 is not dead – yet.
Merck KGaA Wants Your Drugs
Still reeling from the loss of evobrutinib, the German group needs to buy in innovation.
GSK’s Blenrep Comeback On The Cards After Second Trial Win
The DREAMM-8 study was unblinded early thanks to strong interim results, giving Blenrep a shot at returning as a second-line or later treatment for multiple myeloma
Say Goodbye To NASH And Hello To MASH
The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.